Univastu India Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: September 15, 2025, 2:04 pm

Quick Insight

Univastu India Ltd, trading at ₹252 with a market capitalization of ₹303 Cr, presents a mixed financial picture. With a P/E ratio of 26.3 and a healthy ROCE of 26.6%, the company demonstrates efficient capital utilization. Its operating profit margin of 24.92% indicates robust operational efficiency. The company's solid return on equity (ROE) of 15.9% and a comfortable interest coverage ratio (ICR) of 6.81x suggest a strong financial position. However, the high price-to-book value (P/BV) ratio of 3.19x may indicate a potentially overvalued stock compared to industry peers. The negative cash conversion cycle (CCC) of -110 days raises concerns about liquidity management despite healthy reserves of ₹68 Cr.

In the competitive Construction, Contracting & Engineering sector, Univastu India Ltd's heavy reliance on promoters (67.46%) and limited institutional ownership from FIIs and DIIs could impact market liquidity and investor confidence. The company's modest net profit of ₹16 Cr and significant borrowing of ₹35 Cr may expose it to financial risks, especially in a volatile economic environment. Looking ahead, Univastu India Ltd could enhance shareholder value by diversifying its investor base, improving working capital management to address the negative CCC, and exploring avenues for reducing debt to bolster financial resilience. Investors should closely monitor the company's efforts to mitigate risks and capitalize on sector growth opportunities.

In conclusion, while Univastu India Ltd shows strengths in operational efficiency and financial performance, investors should remain vigilant about potential risks stemming from high valuation multiples and liquidity challenges. Diversification of funding sources and strategic financial management will be crucial for the company's sustained growth and long-term value creation in the dynamic construction sector.

Competitors of Univastu India Ltd

All Competitor Stocks of Univastu India Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:45 am

Below is a detailed analysis of the quarterly data for Univastu India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 29.41 Cr.. The value appears to be declining and may need further review. It has decreased from 39.91 Cr. (Mar 2025) to 29.41 Cr., marking a decrease of 10.50 Cr..
• For Expenses, as of Jun 2025, the value is 22.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 32.16 Cr. (Mar 2025) to 22.08 Cr., marking a decrease of 10.08 Cr..
• For Operating Profit, as of Jun 2025, the value is 7.33 Cr.. The value appears to be declining and may need further review. It has decreased from 7.75 Cr. (Mar 2025) to 7.33 Cr., marking a decrease of 0.42 Cr..
• For OPM %, as of Jun 2025, the value is 24.92%. The value appears strong and on an upward trend. It has increased from 19.42% (Mar 2025) to 24.92%, marking an increase of 5.50%.
• For Other Income, as of Jun 2025, the value is 0.17 Cr.. The value appears to be declining and may need further review. It has decreased from 0.49 Cr. (Mar 2025) to 0.17 Cr., marking a decrease of 0.32 Cr..
• For Interest, as of Jun 2025, the value is 1.09 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.02 Cr. (Mar 2025) to 1.09 Cr., marking an increase of 0.07 Cr..
• For Depreciation, as of Jun 2025, the value is 0.41 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.41 Cr..
• For Profit before tax, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.81 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 0.81 Cr..
• For Tax %, as of Jun 2025, the value is 33.17%. The value appears to be improving (decreasing) as expected. It has decreased from 38.18% (Mar 2025) to 33.17%, marking a decrease of 5.01%.
• For Net Profit, as of Jun 2025, the value is 4.01 Cr.. The value appears to be declining and may need further review. It has decreased from 4.22 Cr. (Mar 2025) to 4.01 Cr., marking a decrease of 0.21 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.18. The value appears to be declining and may need further review. It has decreased from 2.34 (Mar 2025) to 2.18, marking a decrease of 0.16.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: September 15, 2025, 4:05 am

Growth

Last Updated: September 5, 2025, 1:50 pm

Balance Sheet

Last Updated: June 16, 2025, 11:08 am

Below is a detailed analysis of the balance sheet data for Univastu India Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2024) to 12.00 Cr., marking an increase of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 41.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 27.00 Cr..
• For Borrowings, as of Mar 2025, the value is 35.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 34.00 Cr. (Mar 2024) to 35.00 Cr., marking an increase of 1.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 72.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 53.00 Cr. (Mar 2024) to 72.00 Cr., marking an increase of 19.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 188.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 139.00 Cr. (Mar 2024) to 188.00 Cr., marking an increase of 49.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 9.00 Cr. (Mar 2024) to 13.00 Cr., marking an increase of 4.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 174.00 Cr.. The value appears strong and on an upward trend. It has increased from 129.00 Cr. (Mar 2024) to 174.00 Cr., marking an increase of 45.00 Cr..
• For Total Assets, as of Mar 2025, the value is 188.00 Cr.. The value appears strong and on an upward trend. It has increased from 139.00 Cr. (Mar 2024) to 188.00 Cr., marking an increase of 49.00 Cr..

Notably, the Reserves (68.00 Cr.) exceed the Borrowings (35.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Univastu India Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 8.68. This value is within the healthy range. It has increased from 6.24 (Mar 24) to 8.68, marking an increase of 2.44.
• For Diluted EPS (Rs.), as of Mar 25, the value is 8.68. This value is within the healthy range. It has increased from 6.24 (Mar 24) to 8.68, marking an increase of 2.44.
• For Cash EPS (Rs.), as of Mar 25, the value is 14.08. This value is within the healthy range. It has increased from 9.86 (Mar 24) to 14.08, marking an increase of 4.22.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.70. It has increased from 47.51 (Mar 24) to 66.70, marking an increase of 19.19.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 66.70. It has increased from 47.51 (Mar 24) to 66.70, marking an increase of 19.19.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 142.70. It has increased from 106.02 (Mar 24) to 142.70, marking an increase of 36.68.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 24.29. This value is within the healthy range. It has increased from 18.14 (Mar 24) to 24.29, marking an increase of 6.15.
• For PBIT / Share (Rs.), as of Mar 25, the value is 23.14. This value is within the healthy range. It has increased from 17.05 (Mar 24) to 23.14, marking an increase of 6.09.
• For PBT / Share (Rs.), as of Mar 25, the value is 19.58. This value is within the healthy range. It has increased from 12.81 (Mar 24) to 19.58, marking an increase of 6.77.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 12.93. This value is within the healthy range. It has increased from 8.77 (Mar 24) to 12.93, marking an increase of 4.16.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.73. This value is within the healthy range. It has increased from 6.24 (Mar 24) to 8.73, marking an increase of 2.49.
• For PBDIT Margin (%), as of Mar 25, the value is 17.02. This value is within the healthy range. It has decreased from 17.11 (Mar 24) to 17.02, marking a decrease of 0.09.
• For PBIT Margin (%), as of Mar 25, the value is 16.21. This value is within the healthy range. It has increased from 16.08 (Mar 24) to 16.21, marking an increase of 0.13.
• For PBT Margin (%), as of Mar 25, the value is 13.71. This value is within the healthy range. It has increased from 12.08 (Mar 24) to 13.71, marking an increase of 1.63.
• For Net Profit Margin (%), as of Mar 25, the value is 9.06. This value is within the healthy range. It has increased from 8.27 (Mar 24) to 9.06, marking an increase of 0.79.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.11. This value is below the healthy minimum of 8. It has increased from 5.88 (Mar 24) to 6.11, marking an increase of 0.23.
• For Return on Networth / Equity (%), as of Mar 25, the value is 13.08. This value is below the healthy minimum of 15. It has decreased from 13.63 (Mar 24) to 13.08, marking a decrease of 0.55.
• For Return on Capital Employeed (%), as of Mar 25, the value is 26.44. This value is within the healthy range. It has decreased from 29.31 (Mar 24) to 26.44, marking a decrease of 2.87.
• For Return On Assets (%), as of Mar 25, the value is 5.57. This value is within the healthy range. It has increased from 5.11 (Mar 24) to 5.57, marking an increase of 0.46.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has increased from 0.02 (Mar 24) to 0.06, marking an increase of 0.04.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.43. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.43, marking a decrease of 0.19.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.05. It has increased from 0.91 (Mar 24) to 1.05, marking an increase of 0.14.
• For Current Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has increased from 1.49 (Mar 24) to 1.73, marking an increase of 0.24.
• For Quick Ratio (X), as of Mar 25, the value is 1.71. This value is within the healthy range. It has increased from 1.48 (Mar 24) to 1.71, marking an increase of 0.23.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 6.81. This value is within the healthy range. It has increased from 4.29 (Mar 24) to 6.81, marking an increase of 2.52.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.63. This value is within the healthy range. It has increased from 3.07 (Mar 24) to 4.63, marking an increase of 1.56.
• For Enterprise Value (Cr.), as of Mar 25, the value is 268.58. It has increased from 182.49 (Mar 24) to 268.58, marking an increase of 86.09.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has increased from 1.51 (Mar 24) to 1.65, marking an increase of 0.14.
• For EV / EBITDA (X), as of Mar 25, the value is 9.68. This value is within the healthy range. It has increased from 8.85 (Mar 24) to 9.68, marking an increase of 0.83.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.49. This value is within the healthy range. It has increased from 1.31 (Mar 24) to 1.49, marking an increase of 0.18.
• For Price / BV (X), as of Mar 25, the value is 3.19. This value exceeds the healthy maximum of 3. It has increased from 3.04 (Mar 24) to 3.19, marking an increase of 0.15.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.49. This value is within the healthy range. It has increased from 1.31 (Mar 24) to 1.49, marking an increase of 0.18.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.04.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness